RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter
© 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd..
Ovarian cancer is one of the most common gynaecological malignancies with poor prognosis and lack of effective treatment. The improvement of the situation of ovarian cancer urgently requires the exploration of its molecular mechanism to develop more effective molecular targeted drugs. In this study, the role of human ribosomal protein l35a (RPL35A) in ovarian cancer was explored in vitro and in vivo. Our data identified that RPL35A expression was abnormally elevated in ovarian cancer. Clinically, high expression of RPL35A predicted short survival and poor TNM staging in patients with ovarian cancer. Functionally, RPL35A knock down inhibited ovarian cancer cell proliferation and migration, enhanced apoptosis, while overexpression had the opposite effect. Mechanically, RPL35A promoted the direct binding of transcription factor YY1 to CTCF in ovarian cancer cells. Consistently, RPL35A regulated ovarian cancer progression depending on CTCF in vitro and in vivo. Furthermore, RPL35A affected the proliferation and apoptosis of ovarian cancer cells through PPAR signalling pathway. In conclusion, RPL35A drove ovarian cancer progression by promoting the binding of YY1 and CTCF promoter, and inhibiting this process may be an effective strategy for targeted therapy of this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of cellular and molecular medicine - 28(2024), 6 vom: 26. März, Seite e18115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Huijuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CCCTC-Binding Factor |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 25.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/jcmm.18115 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369264118 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369264118 | ||
| 003 | DE-627 | ||
| 005 | 20240326235653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jcmm.18115 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM369264118 | ||
| 035 | |a (NLM)38436544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Huijuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. | ||
| 520 | |a Ovarian cancer is one of the most common gynaecological malignancies with poor prognosis and lack of effective treatment. The improvement of the situation of ovarian cancer urgently requires the exploration of its molecular mechanism to develop more effective molecular targeted drugs. In this study, the role of human ribosomal protein l35a (RPL35A) in ovarian cancer was explored in vitro and in vivo. Our data identified that RPL35A expression was abnormally elevated in ovarian cancer. Clinically, high expression of RPL35A predicted short survival and poor TNM staging in patients with ovarian cancer. Functionally, RPL35A knock down inhibited ovarian cancer cell proliferation and migration, enhanced apoptosis, while overexpression had the opposite effect. Mechanically, RPL35A promoted the direct binding of transcription factor YY1 to CTCF in ovarian cancer cells. Consistently, RPL35A regulated ovarian cancer progression depending on CTCF in vitro and in vivo. Furthermore, RPL35A affected the proliferation and apoptosis of ovarian cancer cells through PPAR signalling pathway. In conclusion, RPL35A drove ovarian cancer progression by promoting the binding of YY1 and CTCF promoter, and inhibiting this process may be an effective strategy for targeted therapy of this disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTCF | |
| 650 | 4 | |a RPL35A | |
| 650 | 4 | |a mechanism | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a phenotypic | |
| 650 | 7 | |a Ribosomal Proteins |2 NLM | |
| 650 | 7 | |a RPL35A protein, human |2 NLM | |
| 650 | 7 | |a YY1 protein, human |2 NLM | |
| 650 | 7 | |a YY1 Transcription Factor |2 NLM | |
| 650 | 7 | |a CTCF protein, human |2 NLM | |
| 650 | 7 | |a CCCTC-Binding Factor |2 NLM | |
| 700 | 1 | |a Xia, Liangbin |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiangyu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Hualin |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Jindong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Qinmei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular and molecular medicine |d 2000 |g 28(2024), 6 vom: 26. März, Seite e18115 |w (DE-627)NLM118801236 |x 1582-4934 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:6 |g day:26 |g month:03 |g pages:e18115 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jcmm.18115 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 6 |b 26 |c 03 |h e18115 | ||